Rama Koya, MD
Hematology & Oncology · Longview, TXNPI 1407895832
Payments from drug & device makers
Across 142 payments — averaging $52.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novartis$753
- Beigene USA, Inc.$375
- Athenex Pharmaceutical Division, LLC$350
- Johnson & Johnson$294
- AbbVie$228
- plus $2K from 35 others
What the payments were for
- Consulting fees$3,43346%
- Speaking & faculty fees$3505%
- Travel & lodging$2253%
- Food & beverage$2,42533%
- Education$3905%
- Other$5988%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $3,505 |
| Novartis | 14 | $753 |
| Beigene USA, Inc. | 1 | $375 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Johnson & Johnson(2 entities) | 15 | $294 |
| AbbVie | 7 | $228 |
| GSK | 8 | $147 |
| E.r. Squibb & Sons, L.L.C. | 9 | $144 |
| Incyte Corporation | 5 | $125 |
| Merck | 5 | $118 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Comsort, Inc | 1 | $100 |
| Pfizer | 5 | $99 |
| Amgen | 1 | $95 |
| Myriad Genetic Laboratories, Inc. | 2 | $81 |
| Bayer | 4 | $78 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $70 |
| Astellas Pharma US Inc | 3 | $68 |
| Lilly USA, LLC | 4 | $66 |
| Sobi, Inc | 3 | $66 |
| AVEO Pharmaceuticals, Inc. | 2 | $65 |
| Eisai Inc. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Tempus AI, Inc | 2 | $38 |
| Blueprint Medicines Corporation | 2 | $35 |
| Seagen Inc. | 2 | $32 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $17 |
| Caris MPI, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,421 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 23 | $565,794 |
| CalquenceAcalabrutinib Maleate | 46 | $542,716 |
| ErleadaApalutamide | 34 | $487,916 |
| RevlimidLenalidomide | 35 | $486,987 |
| Lenalidomide | 29 | $464,069 |
| ImbruvicaIbrutinib | 37 | $400,449 |
| JakafiRuxolitinib Phosphate | 29 | $392,235 |
| SprycelDasatinib | 30 | $336,190 |
| PiqrayAlpelisib | 13 | $287,956 |
| TafinlarDabrafenib Mesylate | 19 | $231,213 |
| BrukinsaZanubrutinib | 18 | $223,177 |
| TazverikTazemetostat Hydrobromide | 11 | $149,824 |
| EliquisApixaban | 71 | $60,615 |
| Exemestane | 147 | $23,818 |
| Fentanyl | 43 | $7,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $62 | $565,79423 claims |
| AstraZenecaCalquence | $3,505 | $542,71646 claims |
| NovartisPiqray, Tafinlar | $753 | $519,16932 claims |
| Johnson & JohnsonErleada | $294 | $487,91634 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $70 | $400,44937 claims |
| Incyte CorporationJakafi | $125 | $392,23529 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $144 | $336,19030 claims |
| Beigene USA, Inc.Brukinsa | $375 | $223,17718 claims |
| PfizerEliquis | $99 | $60,61571 claims |
| Lilly USA, LLCOlanzapine | $66 | $11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Longview
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.